^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    clonoSEQ

    Company:
    Adaptive Biotech
    4d
    Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    clonoSEQ
    |
    Xpovio (selinexor)
    7d
    Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jul 2028 --> Nov 2028 | Initiation date: Jan 2026 --> May 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    clonoSEQ
    |
    Carvykti (ciltacabtagene autoleucel) • Hyleukin-7 (efineptakin alfa)
    9d
    CA-4948-203: A Ph2 Study of Emavusertib + an Approved BTKi in Patients with CLL and Other B-cell Malignancies (2025-523600-68-00)
    P1/2, N=40, Not yet recruiting, Curis Inc.
    New P1/2 trial
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • emavusertib (CA-4948)
    10d
    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=53, Recruiting, City of Hope Medical Center | Suspended --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    11d
    EMAT: Elimination of Minimal Residual Disease After Transplant (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    clonoSEQ
    |
    lenalidomide • Sarclisa (isatuximab-irfc) • dexamethasone injection
    14d
    Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=26, Not yet recruiting, City of Hope Medical Center | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date
    |
    CD19 positive
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • cyclophosphamide • Blincyto (blinatumomab) • vincristine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
    14d
    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=53, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    16d
    Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (clinicaltrials.gov)
    P1/2, N=162, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    clonoSEQ
    |
    carfilzomib • pomalidomide • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • dexamethasone injection
    16d
    Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function (clinicaltrials.gov)
    P1, N=16, Recruiting, Washington University School of Medicine | N=12 --> 16 | Trial completion date: Mar 2027 --> May 2028 | Trial primary completion date: Apr 2026 --> Jun 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    clonoSEQ
    |
    cyclophosphamide • Carvykti (ciltacabtagene autoleucel)
    22d
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    clonoSEQ
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    23d
    MRD2STOP: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients (clinicaltrials.gov)
    P=N/A, N=56, Active, not recruiting, University of Chicago | Trial completion date: Feb 2026 --> Apr 2028 | Trial primary completion date: Feb 2026 --> Apr 2028
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    clonoSEQ
    23d
    A041702: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=465, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Dec 2026
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)